Crinetics Pharma gains after early release of study data

magicmine/iStock via Getty Images Crinetics Pharmaceuticals ( NASDAQ: CRNX ) traded higher after the company announced that a data readout accepted for a presentation at a medical event next month was released ahead of schedule. The presentation comprised initial data from four patients who received the company’s oral product candidate CRN04894 in a Phase 2 trial for congenital adrenal hyperplasia, a group of disorders affecting adrenal glands. Crinetics ( CRNX ) is expected to release the readout, including additional data, at the Endocrine Society’s annual meeting (ENDO 2024) on June 3, 2024, from 12:00 to 1:30 p.

m. ET. The four-patient readout indicates that CRN04894, also known as Atumelnant, at 80 mg once daily dosing led to “rapid, profound, and sustained suppression of A4 and 17-OHP,” researchers wrote, referring to the study’s main efficacy goals.

The experimental therapy was well tolerated without any serious or treatment-related adverse events, they added. More on Crinetics Pharmaceuticals Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2024 Earnings Call Transcript Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc.

(CRNX) Q4 2023 Earnings Call Transcript Crinetics Pharmaceuticals Q1 2024 Earnings Preview Crinetics, Syndax gain amid pitch at Sohn charity conference (update).